Navigation Links
Biomerix Corporation Announces FDA Clearance and Market Launch of REVIVE(TM) for Use in Soft Tissue Repair Procedures

FREMONT, Calif., Feb. 26 /PRNewswire/ -- Biomerix Corporation announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance to market REVIVE(TM). Constructed using the Biomerix Biomaterial(TM), REVIVE acts as a tissue scaffold facilitating rapid tissue ingrowth and can be utilized in a variety of soft tissue repair procedures, including the repair of inguinal hernias.

With more than 700,000 procedures per year, inguinal hernia repair is one of the most common surgeries in the U.S.(1) Hernia repair typically involves the use of a mesh to reinforce and support the surrounding tissue. REVIVE is designed to minimize the scarring response that results from implantation of a mesh, which studies have shown can lead to persistent groin pain in 30% of patients at one year(2). Clinical feedback has confirmed REVIVE offers excellent conformability to the defect and ease of handling.(3)

"Biomerix is poised for rapid growth over the course of the next few years. The company plans to launch numerous products across a range of therapeutic areas by capitalizing on its novel Biomerix Biomaterial platform technology. REVIVE is specifically designed to support tissue remodeling by enhancing the soft tissue wound healing process and thereby improves clinical outcomes," stated Kenneth G. Hayes, President and Chief Executive Officer of Biomerix Corporation.

The company has initiated a market launch of REVIVE in the U.S. through a small direct sales force and plans to expand the group over time as additional products are brought to market.

About Biomerix Corporation

Biomerix Corporation develops and manufactures a broad portfolio of implantable medical devices based on its proprietary Biomerix Biomaterial(TM) platform technology. Unique to the Biomerix Biomaterial, is its ability to facilitate fibrovascular tissue in-growth and improve wound healing with a minimal inflammatory response, leading to better clinical outcomes. Biomerix strives to improve patient outcomes through the development of medical devices for soft tissue repair, neurovascular embolization, spine annular repair, cardiovascular repair and women's health indications, utilizing its novel biomaterial.

For more information please call 888.308.3620 or visit

  1. Millenium U.S. Markets for Soft Tissue Repair 2008.
  2. Bay-Nielsen M et. al., "Pain and functional impairment 1 year after inguinal herniorrhaphy: a nationwide questionnaire study," Ann Surg 2001 Jan;233(1):1-7.
  3. Data on file with Biomerix Corporation

SOURCE Biomerix Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
2. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
3. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
4. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
5. BioElectronics Corporation Announces Singapore and Malaysia Sales
6. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
7. DURECT Corporation to Present at the NewsMakers in the Biotech Industry Investment Conference
8. Insulet Corporation to Present at the Thomas Weisel Partners Healthcare Conference on September 6, 2007
9. Luminex Corporation to Present at Thomas Weisel Partners Healthcare Conference
10. Verenium Corporation to Present at the Upcoming Cowen and Company Clean Energy Conference
11. Enova Medical Launches Exos Corporation
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the leading software as ... Clinical Reach Virtual Patient Encounter CONSULT module which enables both audio and video ... trial team. , Using the CONSULT module, patients and physicians can schedule a face ...
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... the funding of a Sponsored Research Agreement with ... tumor cells (CTCs) from cancer patients.  The funding ... CTC levels correlate with clinical outcomes in cancer ... data will then be employed to support the ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader ... “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, ... providing practical tips, tools, and strategies for clinical researchers. , “The landscape of ...
Breaking Biology Technology:
(Date:6/15/2016)... 15, 2016 Transparency Market ... Recognition Market by Application Market - Global Industry Analysis Size ... to the report, the  global gesture recognition market ... and is estimated to grow at a CAGR ... 2024.  Increasing application of gesture recognition ...
(Date:6/3/2016)... 3, 2016 Das ... Nepal hat ein 44 ... geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, ... Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte ... Januar teilgenommen, aber Decatur wurde als konformste ...
(Date:6/1/2016)... , June 1, 2016 ... in Election Administration and Criminal Identification to Boost Global ... a recently released TechSci Research report, " Global Biometrics ... Region, Competition Forecast and Opportunities, 2011 - 2021", the ... billion by 2021, on account of growing security concerns ...
Breaking Biology News(10 mins):